Clinical Trial Record

Return to Clinical Trials

Studying Biomarkers in Patients With Pancreatic Cancer


2007-05


2013-03


2013-03


53

Study Overview

Studying Biomarkers in Patients With Pancreatic Cancer

RATIONALE: Studying samples of tissue in the laboratory from patients with cancer may help doctors identify and learn more about biomarkers related to cancer. It may also help doctors predict how patients will respond to treatment. PURPOSE: This research study is studying biomarkers in patients with pancreatic cancer.

OBJECTIVES: * To determine whether the cellular localization of BRCA1 can predict how patients with pancreatic cancer will respond to cytotoxic agents (e.g., fluorouracil or gemcitabine hydrochloride) or radiotherapy. * To identify pre-treatment markers that can be used to correlate with clinical outcomes of survival and recurrence. * To determine if a method of extracting and identifying secreted cytokines and growth factors from biopsy tissue can now be applied to the pancreatic cancer population. OUTLINE: Tissue samples from biopsies performed during pancreatectomy are collected from the Vanderbilt Ingram Cancer Center Human Tissue Acquisition Core for laboratory biomarker studies. Proteins secreted by cancer cells and/or cancer-associated cells are studied by extracting and identifying secreted cytokines and growth factors from biopsy tissue. The integrity of the DNA repair pathway in pancreatic cancer is analyzed by Rad51 and phosphorylated DNA-PK foci formation. Markers are correlated with clinical outcome. Patients are followed for recurrence, relapse, and death from disease.

  • Pancreatic Cancer
  • GENETIC: protein analysis
  • OTHER: laboratory biomarker analysis
  • VICC GI 0717
  • P30CA068485 (U.S. NIH Grant/Contract)
  • VU-VICC-GI-0717
  • VU-VICC-070366

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates Results Reporting Dates Study Record Updates

2009-05-09  

N/A  

2013-12-10  

2009-05-09  

N/A  

2013-12-12  

2009-05-12  

N/A  

2013-12  

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

Design Details

Primary Purpose:
N/A


Allocation:
N/A


Interventional Model:
N/A


Masking:
N/A


Arms and Interventions

Participant Group/ArmIntervention/Treatment
: pancreatic cancer patients

pancreatic cancer patients with excess tissue collected at the time of standard of care surgery

GENETIC: protein analysis

  • Using material that is already being acquired as a component of clinical care (only that which is excess after routine clinical care), we will determine if pre-treatment markers can be used to correlate with clinical outcomes of survival and recurrence. E

OTHER: laboratory biomarker analysis

  • A method of extracting and identifying secreted cytokines and growth factors from tissues of the quantity of typical biopsy tissues has been developed.The purpose of this study is to determine if this method of biomarker discovery can now be applied to pa
Primary Outcome MeasuresMeasure DescriptionTime Frame
Cellular localization of BRCA1 as a predictor of response to cytotoxic agents or radiotherapyExamine the location of BRCA1 in the cells and determine if this location predicts patient response to the chemotherapy drugs givenfollowing collection of all pancreatic tissue specimens and patient outcome data
Secondary Outcome MeasuresMeasure DescriptionTime Frame
Correlation of pre-treatment markers with survival and recurrenceCompare and contract of biomarkers in patient's tissue that are detected before treatment has a relationship to their survival and recurrence of their cancerat expiration date of final patient enrolled
Application of a method of extracting and identifying secreted cytokines and growth factors from biopsy tissue to the pancreatic cancer populationResearchers will determine if the methods they have developed for extracting and identifying cytokines in biopsy tissue can be applied to the pancreatic cancer tissueupon collection of pancreatic tissue for each patient

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person’s general health condition or prior treatments.

Ages Eligible for Study:
ALL

Sexes Eligible for Study:

Accepts Healthy Volunteers:

    Inclusion criteria

  • Any subject with excess tissue collected at time of routine surgery for pancreatic cancer is eligible.
  • All subjects participating in this protocol will be followed for recurrence, relapse and death from disease

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

  • National Cancer Institute (NCI)

  • STUDY_CHAIR: A. Bapsi Chakravarthy, MD, Vanderbilt-Ingram Cancer Center

Publications

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

No publications available